Pathophysiology of dyslipidemia in Cushing's syndrome.

@article{Arnaldi2010PathophysiologyOD,
  title={Pathophysiology of dyslipidemia in Cushing's syndrome.},
  author={Giorgio Arnaldi and Valerio Mattia Scandali and Laura Trementino and Marina Cardinaletti and Gloria Appolloni and Marco Boscaro},
  journal={Neuroendocrinology},
  year={2010},
  volume={92 Suppl 1},
  pages={86-90}
}
Dyslipidemia seems to be less frequent than other metabolic comorbidities in human Cushing's syndrome. Nevertheless, it plays an important role in determining the global cardiovascular risk in overt and subclinical Cushing's syndrome. In Cushing's syndrome, there is an increase of triglyceride and total cholesterol levels whereas HDL can be at variable levels. Overt and subclinical Cushing's syndrome share many features with metabolic syndrome including insulin resistance, abnormal fasting… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

[Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy].

La Revue de medecine interne • 2013
View 7 Excerpts
Highly Influenced

Could Lipid Profile be Used as a Marker of Autonomous Cortisol Secretion in Patients with Adrenal Incidentalomas?

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme • 2018

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Similar Papers

Loading similar papers…